Keyword
Quick search:
Content Search
Result Content Research
Result Content Research
1 Inside Vertex 3.0: Can Reshma Kewalramani repeat one of biotech's biggest success stories 'again and again and again'?
2 The Top 25 CEOs who earned the highest pay last year was a men's only club
3 CTX001 Continues to Show Promise in Severe Sickle Cell Disease
4 UPDATED: The numbers are in, and new Vertex CEO Reshma Kewalramani took home half of what predecessor Jeff Leiden did in his last year on the job
5 Is CRISPR Therapeutics a Millionaire-Maker Stock?
6 Vertex CEO Reshma Kewalramani to Receive Golden Door Award
7 2 Top Biotech Stocks to Buy Right Now
8 Trailblazers: Vertex CEO Reshma Kewalramani on Leadership, STEM, Diversity, Inclusion and Medicine on Chai With Manju
9 Watch: A Curated Conversation with Reshma Kewalramani, president and CEO of Vertex
10 Women Who Mean Business: Reshma Kewalramani
11 Vertex CEO faces growing pressure for pipeline deals despite major hike in Trikafta sales
12 Here's how Mass. companies handled pandemic-era CEO turnover
13 Trailblazing MED Alum to Lead Vertex Pharmaceuticals | Bostonia
14 Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani Presents at Cowen 41st Annual Health Care Conference (Transcript)
15 Vertex CEO says it has the ‘financial firepower’ to make more deals
16 Vertex Looks to Expand Portfolio with Mid- and Late-Stage Assets
17 Vertex Pharmaceuticals names Chief Medical Officer Reshma Kewalramani as new CEO
18 Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With Cystic Fibrosis as Early as Four Months of Age
19 A $43 Billion Biotech Now Has a Female CEO: Brainstorm Health
20 Vertex Appoints Reshma Kewalramani, M.D., as Chief Medical Officer
21 Top analyst maps a rocky road for Vertex — unless they adopt a $10B M&A campaign to save the pipeline
22 Vertex Receives Australian TGA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have At Least One F508del Mutation
23 Vertex Reports First-Quarter 2021 Financial Results
24 Vertex Shares Fall as AATD Drug Fails. Analysts Say It's Time to Buy.
25 Vertex Stock Fell After a Setback on a New Drug. It’s an Opportunity for Investors.
26 Vertex Appoints First Female CEO
27 The top 15 highest-paid biopharma CEOs of 2020
28 Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del Mutation
29 Vertex Looks to Expand Asset Portfolio – PharmaLive
30 This Bold Statement by the Vertex CEO Means a New Blockbuster May be Here Soon
31 Vertex Buys Majority Rights to Gene-Editing Therapy From CRISPR
32 Book traversal links for 2020's Fiercest Women in Life Sciences
33 Vertex Announces European Commission Approval for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older With At Least One F508del Mutation in the CFTR gene
34 Vertex's planned CEO handoff could signal stagnant growth to come: analyst
35 Vertex Reports Third-Quarter 2020 Financial Results
36 CORRECTING and REPLACING Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
37 The Vertex Foundation Gives $1.5 Million to New BU Center for Antiracist Research
38 Trikafta Approved in Australia for CF Patients Starting at Age 12
39 Vertex Abandons VX-814 Program for Treating Rare Liver Disease
40 Vertex Pharmaceuticals enters new era of leadership with CEO Reshma Kewalramani
41 A record 41 women are Fortune 500 CEOs—and for the first time two Black women made the list
42 FDA Expands Vertex CFTR Modulators Labels for More CF Mutations
43 Summit 2020
44 Vertex Announces European Commission Approval for SYMKEVI® (tezacaftor/ivacaftor) With KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 6-11 Years
45 Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting
46 Kaftrio Opens to All CF Patients, 12 and Up, in EU With F508del...
47 Vertex Pharma: FDA Approves Expanded Use of Trikaftato in Children
48 Health Canada Approves Trikafta for CF Patients, Ages 12 and Up
49 Vertex wins broader label for Trikafta in the USA
50 Vertex stops work on second rare disease drug after study results disappoint
51 CEO Salaries for the Top 20 Pharma Companies by Market Cap
52 Moncef Slaoui, who led US Warp Speed effort, accused of sexual harassment
53 FDA fast tracks type 1 diabetes cell therapy from Vertex
54 Vertex bolsters C-suite with new CMO, chief regulatory officer
55 Vertex Announces FDA Approvals of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Use in People With CF With Certain Rare Mutations
56 Vertex, CRISPR Therapeutics' blood disorder gene therapy shows more promise
57 Vertex urged to address 'fatal inequality' in access to its cystic fibrosis drug
58 FDA approves expanded use of three cystic fibrosis therapies
59 Merck CEO Frazier joins army of Black execs speaking out on restrictive voting-rights laws
60 Top 16 Highest-Paid Women CEOs in the Biopharma Industry
61 Indiaspora raises over $1 million for COVID relief from diaspora leaders in 48 hours
62 3 Reasons Vertex Is Still a Buy After Its Recent Pipeline Setback
63 Motley Fool: Vertex Pharma’s drug pipeline looks promising
64 Symkevi-Kalydeco Combo Approved in Europe to Treat CF Patients...
65 Kalydeco Open to Infants in Europe Starting at 4 Months Old
66 A year out from FDA approval, Vertex looks to expand top-selling CF drug to pediatrics
67 Vertex and the Vertex Foundation Commit $4 Million to Support Racial Equity and Social Justice
68 Here are the BBJ's 2020 Women Who Mean Business honorees
69 FDA Approves CF Treatment Kalydeco for Infants as Young as 4 Months
70 Gene-Editing Therapy CTX001 Reports Durable Effects for TDT, Sickle Cell Patients
71 Employees in Florida IBS trial plead guilty for falsifying medical records; Cystic fibrosis tablet Trikafta now available for children 6 and older
72 JPMorgan Healthcare Conference: Gilead, Biogen Lead Companies That Need Deals
73 I embrace what makes me different and view it as an advantage: Vimeo CEO Anjali Sud
74 Women Who Mean Business: Myechia Minter-Jordan
75 Transforming Business | 300 People transforming business
76 We're looking for 2020's Fiercest Women in Life Sciences
77 Merck CEO Frazier takes voting-rights fight nationwide, with help from a bigger group of influential execs
78 NHS, Vertex Strike Deal to Make Kaftrio Available in England
79 Vertex Triple Combo, Kaftrio, Approved for CF Patients in EU With...
80 Vertex Reports First-Quarter 2020 Financial Results
81 Where to Invest $5000 Right Now
82 Vertex's cystic fibrosis drugs work, but they're too expensive, ICER finds
83 Vertex CEO: How Jeffrey Leiden Turned Brilliance Into Billions
84 Merck KGaA appoints Belén Garijo its CEO
85 Vertex Announces Expansion of Reimbursement Agreement With NHS England to Include KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO® (ivacaftor)
86 Merck KGaA names Garijo CEO, punching another hole in biopharma's glass ceiling
87 Chutes & Ladders—Gilead's commercial head leaves sales challenges behind
88 What Does Biden’s Approach To Immigration Mean For CEOs?
89 Ibram X. Kendi and BU's Center for Antiracist Research | Bostonia
90 ADDING MULTIMEDIA FDA Approves TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation
91 Vertex doubles down on gene editing with two new partnerships
92 JPM, Day 1: Moderna's 'inflection year,' Gilead's Veklury boost, Genentech's 'silver linings'
93 Phase 3 Results from Two Studies of TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Triple Combination Treatment for Cystic Fibrosis Concurrently Published in The New England Journal of Medicine and The Lancet
94 Regeneron, Novavax CEOs Top List of Highest Paid in 2020
95 Chutes & Ladders—Vertex appoints BMS vet Atkinson to head manufacturing
96 Vertex sets higher 2020 revenue target due to 'remarkable' cystic fibrosis drug sales
97 Five things you need to know today, and New Englanders of the year
98 Cystic fibrosis life-altering drug nearing patient access across the country: Health Canada
99 UPDATED: Vertex strikes out on its latest big shot at a rare genetic disease. But they're going to keep on swinging
100 Is Pharma Too Introspective to be Truly Innovative?